Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Net Income (2020 - 2025)

Historic Net Income for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Pliant Therapeutics' Net Income rose 5446.74% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.5 million, marking a year-over-year increase of 1298.19%. This contributed to the annual value of -$210.3 million for FY2024, which is 3035.16% down from last year.
  • Pliant Therapeutics' Net Income amounted to -$26.3 million in Q3 2025, which was up 5446.74% from -$43.3 million recorded in Q2 2025.
  • Over the past 5 years, Pliant Therapeutics' Net Income peaked at -$22.8 million during Q2 2021, and registered a low of -$57.8 million during Q3 2024.
  • Moreover, its 5-year median value for Net Income was -$37.5 million (2023), whereas its average is -$37.8 million.
  • As far as peak fluctuations go, Pliant Therapeutics' Net Income tumbled by 30723.55% in 2021, and later surged by 5446.74% in 2025.
  • Over the past 5 years, Pliant Therapeutics' Net Income (Quarter) stood at -$24.5 million in 2021, then tumbled by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then surged by 47.11% to -$26.3 million in 2025.
  • Its Net Income stands at -$26.3 million for Q3 2025, versus -$43.3 million for Q2 2025 and -$56.2 million for Q1 2025.